The Clinical Data Interchange Standards Consortium
(CDISC) is delighted to announce the opening of a branch of the CDISC European Foundation in Hong Kong. Hong Kong was chosen for its centralized location in the fastest growing market in the world, and represents a significant opportunity for CDISC to expand the global adoption of CDISC standards. “Our presence in Hong Kong reflects our commitment to our existing and new members in the Asia-Pacific region. This includes existing member companies in such Asia-Pacific countries as Japan, China, South Korea, India, Thailand, Singapore and Australia. We at CDISC want to ensure that our members in this region feel that they have an outlet and are represented,” stated Sheila Leaman, CDISC Director of Global Relations.
After a vision that took nine months to come to fruition, the registration of the Hong Kong branch was finalized on 7 May 2013. “We are extremely pleased to announce our new CDISC Hong Kong branch,” said Dr. Rebecca Kush, CDISC President and CEO. “After discussions within CDISC Operations last year, we determined to proceed through our CDISC European Foundation entity to allow for a swifter process, and are glad that we will now have representation for our members in the Asia-Pacific region.”
Incidentally, after CDISC’s successful Interchange in Singapore in February 2013, attendees were interested in continuing to have a CDISC conference in the region. As such, CDISC is planning to have the next CDISC Asia-Pacific Interchange in Hong Kong in the summer of 2014 as a way to continue to provide value to our members and spread the message about CDISC standards in the region.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.